EVP-0962
- Generic Name
- EVP-0962
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease
Phase 2
Completed
- Conditions
- Mild Cognitive ImpairmentAlzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 52
- Registration Number
- NCT01661673
- Locations
- 🇺🇸
Glendale Adventist Medical Center, Glendale, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath